Hepatobiliary cancer refers to primary malignant tumors originating in cells of the liver, bile ducts, and gallbladder. Globally, primary liver cancer, which includes hepatocellular carcinoma (~75 % of all cases) and intrahepatic biliary cancer or cholangiocarcinoma (~10-15 % 0f all cases) is the 6th most commonly diagnosed cancer and 3rd leading cause of cancer deaths worldwide. The vast majority of these highly malignant cancers are diagnosed at an advanced stage where treatment options are limited and patient survival outcomes are poor. The biological and therapeutic challenges posed by hepatobililiary cancers such as hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) are daunting, emphasizing a critical need to review and assess current and evolving basic, translational, and clinical research focused on addressing the critical obstacles that continue to limit progress towards achieving significant improvements in HCC and CCA clinical management and patient survival outcomes. Towards this goal, this special edition of Advances in Cancer Research is focused on providing a comprehensive, timely and authoritative reviews covering such topics of significant scientific and clinical relevance, including hepatobiliary cancer risk mechanisms and risk-predictive molecular biomarkers; causes and functional intricacies of inter- and intratumor heterogeneity; novel insights into the role of tumor microenvironment and key signaling pathways in promoting hepatobiliary cancer progression, therapeutic resistance and immunosuppression; emerging biomarkers of HCC and CCA prognosis; advances in molecular genomics for personalizing tumor classification and targeted therapies; innovative preclinical cell culture modeling for hepatobiliary cancer drug discovery; and current and emerging trends in hepatobiliary cancer molecular therapeutic targeting and immunotherapies.
Up-to date review of hepatobiliary cancers molecular genetics, novel predictive molecular biomarkers, and distinct mechanisms of inter-and intratumor heterogeneity Novel insights into the role of tumor microenvironment as a promoter of hepatobiliary cancer progression and therapeutic resistance, as well as an emerging therapeutic target Current and emerging approaches and strategies for advancing personalized molecular therapeutic targeting and immunotherapy of hepatobiliary cancers
-도서목차-
Cover image Title page Table of Contents Copyright Contributors Preface Chapter One: Liver cancer risk-predictive molecular biomarkers specific to clinico-epidemiological contexts Abstract 1: Introduction 2: Clinico-epidemiological contexts relevant to liver cancer risk 3: Molecular indicators of high-risk liver 4: Host and systemic factors associated with liver cancer risk 5: Clinical implementation of molecular liver cancer risk assessment 6: Conclusion Acknowledgments Conflict of interest References Chapter Two: Inflammatory pathways and cholangiocarcinoma risk mechanisms and prevention Abstract 1: Introduction 2: Diseases prodromal to cholangiocarcinoma development 3: Mechanisms of neoplastic transformation 4: Role of inflammatory cells in modulating CCA malignant features 5: Conclusions Grant support Conflict of interest statement References Chapter Three: Causes and functional intricacies of inter- and intratumor heterogeneity of primary liver cancers Abstract 1: Introduction 2: Liver cancer heterogeneity 3: Spatial architecture and tumor heterogeneity 4: Concluding remarks and future perspectives Acknowledgments Author contributions Declaration of interests References Chapter Four: Implications of genetic heterogeneity in hepatocellular cancer Abstract 1: Introduction 2: Approaches to studying heterogeneity in HCC 3: Molecular heterogeneity in HCC 4: Clinical implications of genetic heterogeneity in HCC 5: Therapeutic implications of genetic heterogeneity in HCC 6: Current perspectives and future directions Acknowledgements Grant support Conflict of interest statement References Chapter Five: Understanding the genetic basis for cholangiocarcinoma Abstract 1: Introduction 2: Germline mutations in risk factors associated with cholangiocarcinoma 3: Overview of germline mutations and variants associated with cholangiocarcinoma 4: Key candidate gene studies of CCA risk variants 5: Pathogenic germline alteration (PGA) sequencing studies 6: Conclusion Conflict of interest statement Grant support References Chapter Six: Novel insights into molecular and immune subtypes of biliary tract cancers Abstract 1: Introduction 2: The mutational landscape of biliary tract cancers 3: Multi-omics classifications of intrahepatic cholangicoarcinoma 4: Molecular classifications of other biliary tract cancers 5: Therapeutic implications 6: Conclusions and future perspectives Acknowledgments Grant support Conflict of interest statement References Chapter Seven: Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma progression and therapeutic resistance Abstract 1: Introduction 2: Tumor microenvironment in iCCA 3: Cancer-associated fibroblasts in iCCA 4: Role of cancer-associated fibroblasts in iCCA 5: Therapeutic relevance of cancer associated fibroblasts in iCCA 6: Current and future perspectives Acknowledgment Grant support Conflict of interest References Chapter Eight: Mechanisms and clinical significance of TGF-β in hepatocellular cancer progression Abstract 1: Introduction 2: Overview of the TGF-β pathway 3: TGF-β signaling in liver homeostasis 4: Mouse models for TGF-β-Smad signaling in HCC development and progression 5: TGF-β pathway activity in HCC patients Grant support Conflict of interest statement References Chapter Nine: Matricellular proteins in intrahepatic cholangiocarcinoma Abstract 1: Introduction 2: Overview of classes, structures, and complexities of matricellular proteins aberrantly expressed in iCCA 3: Matricellular proteins as modulators of iCCA microenvironment and malignant progression 4: Clinical relevance of matricellular proteins in iCCA 5: Perspectives and conclusions Grant support Conflict of interest statement References Chapter Ten: YAP1 activation and Hippo pathway signaling in the pathogenesis and treatment of intrahepatic cholangiocarcinoma Abstract 1: Introduction 2: Overview of Hippo-YAP1 signaling pathway 3: Biologic function and pathologic impact of Hippo-YAP1 pathway in ICCA 4: Clinical relevance and therapeutic potential of modulation of Hippo-YAP1 pathway in ICCA 5: Concluding remarks Acknowledgments Conflict of interest statement References Chapter Eleven: Patient-derived functional organoids as a personalized approach for drug screening against hepatobiliary cancers Abstract 1: Introduction 2: Hepatobiliary cancer treatment: Challenges 3: Tumor organoids for personalized drug screening 4: Conclusion and future perspectives Grant support Conflict of interest statement References Chapter Twelve: Molecular therapeutic targets for cholangiocarcinoma: Present challenges and future possibilities Abstract 1: Introduction 2: Genomic alterations as therapeutic targets in CCA 3: Non-genomic alterations as therapeutic targets in CCA 4: Present challenges and future possibilities for therapeutic targets in CCA 5: Predictive Biomarkers & Treatment Resistance 6: Current & future perspectives Acknowledgment Conflict of interest statement References Chapter Thirteen: Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies Abstract 1: The immune biology of the liver 2: The immunosuppressive environment of hepatocellular carcinoma 3: Immunotherapy of HCC 4: Immunotherapy of intrahepatic cholangiocarcinoma 5: Concluding remarks Grant support Conflict of interest References Chapter Fourteen: Immunotherapy for hepatobiliary cancers: Emerging targets and translational advances Abstract 1: Introduction 2: Emerging targets for liver cancer immunotherapy 3: The role of GPC3 in HCC 4: The role of mesothelin in iCCA 5: Conclusion and future perspectives Acknowledgments Conflict of interest statement Grant support References
기타 의학도서에 관련된 문의사항은 고객센터(02-854-2738) 또는 저희 성보의학서적 홈페이지내 도서문의 게시판에 문의바랍니다. 감사합니다. 성보의학서적 "http://www.medcore.kr